P561: VIALE-T: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Charles Craddock(University Hospitals Birmingham NHS Foundation Trust), Johannes Wolff(The University of Texas MD Anderson Cancer Center), Sadiya N. Addo(AbbVie (United States)), Michael Heuser(Martin Luther University Halle-Wittenberg), Brenda Chyla(AbbVie (United States)), P. Lee(AbbVie (United States)), Sonali Chaudhury(Northwestern University), Uwe Platzbecker(National Center for Tumor Diseases), Qi Jiang(AbbVie (United States)), Depei Wu(Zhejiang Chinese Medical University), Vinod Pullarkat(City of Hope)
Cited by 7
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k